The price gap
Brand-name semaglutide and tirzepatide list at $900–$1,350/month before insurance. Compounded versions of the same active ingredients are available through reputable telehealth programs at $145–$300/month. The 5–10× spread is not explained by manufacturing cost — peptide synthesis at scale is not particularly expensive. It is explained by the regulatory and commercial framework around what a manufacturer can charge for an FDA-approved drug with patent protection.
What manufacturer cash-pay programs do
Eli Lilly's LillyDirect program (and Novo Nordisk's narrower analog) acknowledge the price gap and offer reduced cash-pay pricing on authentic FDA-approved product — typically $399–$599/month for tirzepatide single-dose vials. These programs sit roughly in the middle of the price spectrum, providing a regulated middle option between brand-name list pricing and compounded preparations.
They are also, structurally, a manufacturer concession that the brand-name list price is not a true clearing price for the cash-pay market. The negotiated rate, the manufacturer rebate net price, and the cash-pay price are three different numbers — and the cash-pay price is the one most relevant to patients without coverage.
What a coherent policy would do
We don't take positions on specific policy proposals. But the underlying observation that cash-pay GLP-1 pricing is a policy-shaped market — rather than a market-clearing equilibrium — is worth surfacing. The patient who cannot afford brand-name product and is making a choice between compounded preparations is operating in the gap left by that policy choice, not in a market failure that legislation cannot reach.
The corollary, for editorial integrity: the comparative shopping advice we give in the rankings is downstream of policy choices we are not making. It is a way of helping patients navigate the system as it exists, not an endorsement of the system as it exists.